Why Choosing The Right CDMO Partner Is Essential In Today's Pharmaceutical Market

Drug developers are employing novel therapies developed with innovative, cutting-edge technology to target and treat diseases with previously unmet medical needs. As regulatory bodies aim to keep pace with the rapid technological advances taking place in the biopharmaceutical industry – particularly when it comes to next-generation therapies – the regulatory framework is growing more complex, making it difficult for drug manufacturers to not only maintain compliance but also to bring new molecules into the clinical stage and forward to commercialization.

Daniel Buckley, Associate Director of CDO Downstream Development at Samsung Biologics, discusses why it is essential for biotechs to choose the right contract development and manufacturing partner for drug development success in this market landscape.